PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|November 12, 2014
Essentra to Acquire Clondalkin's Specialist Packaging Division
Author(s)Pharmaceutical Technology Editors
Essentra has signed an agreement to acquire Clondalkin's Specialist Packaging Division for a cash consideration of approximately $455 million.
Advertisement
Essentra has signed an agreement to acquire Clondalkin’s Specialist Packaging Division for a cash consideration of approximately $455 million. According to the press release, the transaction marks Essentra’s largest acquisition to date and is expected to complete in the first quarter of 2015.
Clondalkin SPD is a global provider of speciality secondary packaging solutions for the pharmaceutical and health and personal care industries, with 24 facilities. It is believed that the acquisition will add to Essentra’s position in these markets.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement